Thus, our findings unravel a novel molecular mechanism by which ebselen ameliorates insulin resistance and protects against oxidative stress and chronic inflammation and highlights the potential of SHIP2 as a drug target to treat metabolic disorders. The gene discussed is INPPL1; the disease is Other metabolic disease.